Resistance: latest news

Resistance resources

  • My drugs chart

    My drugs chart provides information on all the anti-HIV drugs currently licensed for use in Europe.Select your chosen drugs and drag them onto the area...

    From: My drugs chart

  • What is drug resistance?

    One of the possible consequences of not taking your HIV treatment properly is that your HIV will develop resistance to anti-HIV drugs. This section of the booklet provides...

    From: Booklets

    Information level Level 2
  • Taking your HIV treatment

    This booklet is a starting point for anyone who wants to know about treatment for HIV. It provides basic information about how HIV treatment works...

    From: Booklets

    Information level Level 2
  • Resistance tests

    This factsheet provides basic information on tests designed to measure resistance to anti-HIV drugs. Resistance testing has been used in HIV research for some time to...

    From: Factsheets

    Information level Level 2
  • Resistance

    HIV can become resistant to the drugs used to treat it. This is because HIV changes, or mutates, slightly every time it reproduces itself. Some...

    From: Factsheets

    Information level Level 2
  • Drug resistance

    It's important to always take your HIV treatment at the right times and in the right amounts. If you don't, HIV may become drug resistant.When...

    From: The basics

    Information level Level 1
  • An HIV treatment journey

    This illustrated leaflet shows the journey a lot of people go on with HIV treatment. It involves the decision to start treatment, problems with side...

    From: The basics

    Information level Level 1
  • Drug resistance

    HIV reproduces in the body very quickly, making billions of new viruses every day by replicating its genetic material. HIV is a retrovirus; retroviruses have an inherently high...

    From: HIV treatments directory

    Information level Level 4

Resistance in your own words

Resistance news from aidsmap

More news

Resistance news selected from other sources

  • HIV and drug resistance

    A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.

    09 February 2016 | UNAIDS
  • HIV resistance to favored treatment not uncommon

    Resistance to a key HIV drug is common worldwide and could mean trouble for treating and preventing the virus that causes AIDS, according to a new study.

    29 January 2016 | Reuters
  • Undetectable & Low-level HIV Viral Replication

    Even people who are adherent to their medication regimens may experience occasional “blips” in their viral loads, experience viral rebound or maintain a steady, if low, viral load above undetectable levels. To understand why some people struggle to achieve or remain undetectable, we spoke with Keith Henry, MD, an HIV specialist at Hennepin County Medical Center who has more than 25 years of experience caring for people with HIV.

    06 January 2016 | BETA blog
  • 'Super-gonorrhoea' outbreak across north of England sparks national alert

    An outbreak of highly drug-resistant gonorrhoea has been detected in the north of England, triggering a national alert. Fifteen cases, all in heterosexuals, have been detected by Public Health England (PHE) so far, the British Association for Sexual Health and HIV said.

    18 September 2015 | Daily Telegraph
  • Can we ensure adherence to STI treatment guidelines in a world threatened by antimicrobial resistance?

    Sexual health care in the UK has traditionally centred on specialist GUM (genito-urinary medicine) services. Since the turn of the twenty-first century primary care has played an increasing role, however. The 2012 Health and Social Care Act is in line with this tendency, with most GP practices now being commissioned to provide level 1 STI screening. Questions have recently been raised about the conformity of care provided by GPs to national guidelines, established for the UK by the British Association for Sexual Health and HIV. In a world where Gonorrhoea – and perhaps one day Chlamydia – is set to become increasingly hard to treat, the problem of ensuring the conformity of generalists to universal standards of treatment is unlikely to go away.

    26 August 2015 | BMJ
  • Pretreatment HIV drug resistance leads patients to switch to second-line ART

    Recent data suggested that retreatment HIV drug resistance in sub-Saharan Africa was associated with a nearly fourfold increase in switching to second-line ART, but did not influence mortality or AIDS-related events.

    11 August 2015 | Healio
  • Limited Number of Mutations Responsible for Drug-Resistant HIV

    "What we are showing is that the rates of transmitted drug-resistant HIV in the low- and middle-income countries most affected by HIV have increased modestly. The rate of increase in sub-Saharan Africa has been low, and an increase has not been detected in south Asia and Southeast Asia. That's good news," said Robert Shafer, M.D., professor of medicine at Stanford and principal investigator on the study.

    08 April 2015 | Genetic Engineering & Biotechnology News
  • Exploring possible treatment options after virological failure with raltegravir

    In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

    21 January 2015 | CATIE
  • New anti HIV drug dolutegravir is effective at low doses

    The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.

    21 January 2015 | MMD Newswire
  • Drug Resistance, While Rare, Can Occur After Contracting HIV on PrEP

    For the first time, a study has shown that, although rare, resistance to Truvada can develop if someone contracts HIV while taking the drug as PrEP.

    16 January 2015 | AIDSMeds
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.